Novasep is acquiring Henogen thus adding a range of upstream processing capabilities and services to its downstream processing (DSP) offerings. Novasep reports that with this acquisition it will be able to offer a complete manufacturing solution for antibody-drug conjugates, covering early development to future commercial production.
Henogen has more than 100 employees and operates two biomanufacturing facilities south of Brussels. It will become a part of Novasep Process, the biomolecules division. Henogen brings experience with an extensive array of expression tools including E. coli, yeast, L. lactis, insect and mammalian cells, as well as viral vectors.
The two companies have previously cooperated on biomanufacturing projects. Combined services to be offered with this takeover now include upstream and downstream processing, contract biomanufacturing services, as well as chromatography and membrane-filtration technologies.